PMS2 K706FS*19

CI-VAR-00002170Explore in graph →NP_000526.2:p.Lys706SerfsNM_000535.6:c.2117delAClinVar 142765 CIViC 508 rs587782704

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Glioblastoma1
PMS2 K706FS*19	Nivolumab	Predictive	C	Supports Sensitivity Response	4	accepted	EID1214 Two siblings (6 and 3.5 years) from nonconsanguineous parents were diagnosed with glioblastoma multiforme. Both tumors harbored TP53 mutations and lack of MGMT promoter hypermethylation as poor progno… (full text at CIViC) PMID 27001570 · Bouffet et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
142765	Pathogenic	criteria provided, multiple submitters, no conflicts	2	Hereditary cancer-predisposing syndrome; Lynch syndrome; Hereditary nonpolyposis colorectal neoplasms; Lynch syndrome 4; Endometrial carcinoma; Hereditary nonpolyposis colon cancer; PMS2-related disorder	germline	20	Jan 26, 2026